|
Article Excerpt
Digestive Disease Week 2006, an international medical congress, held in Los Angeles, USA, between May 20-25, brought together more than 16,000 physicians specializing in the field of gastroenterology.
In addition to advances in diagnosis and surgery, conference attendees heard presentations on interventions from across the whole spectrum of GE medicines, from early-stage clinical data on emerging drugs, to post-marketing studies on standard-of-care agents. Among these, Swiss drug major Novartis presented new data on its approved serotonin receptor antagonist Zelnorm (tegaserod maleate).
The firm stated that a randomized, double-blind, placebo-controlled, multicenter study, which evaluated 661 women with constipation-predominant irritable bowel syndrome (IBS-C) or irritable bowel syndrome with a mixed bowel pattern (IBS-M), found that it was...
|
|
More articles from Pharma Marketletter
Senior appointments at Neurochem., May 29, 2006
Study shows atomoxetine's efficacy as ADHD treatment., May 29, 2006
Roche's Copegus/Pegasys "cost effective," study., May 29, 2006
Sequenom recruits Elizabeth Dragon to lead R&D., May 29, 2006
MedImmune hires Peter Greenlead as senior VP, marketing and sales., May 29, 2006
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
